May 29, 2013 | According to a study done by Tufts Center for the Study of Drug Development (CSDD), roughly 20% of ongoing clinical trials are currently using adaptive designs, and usage of these methods are expected to increase in the exploratory phase of drug development. According to the study, widespread use of adaptive designs have the potential to save sponsors hundreds of millions of dollars by making pre-planned modifications, such as terminating studies early. PharmaTimes